Managing EPS in antipsychotic therapy Archives - Clinical Cure

Risperidone Induced Extrapyramidal Side Effects

Sep 14, 2024 By hemanthbesabathini@gmail.com Research & Publications Akathisia, Antipsychotic-induced akathisia, Antipsychotics and involuntary movements, Dopamine antagonism and EPS, Dopamine receptor blockade, EPS symptoms in psychiatric treatment, Extrapyramidal symptoms, Managing EPS in antipsychotic therapy, Managing side effects of antipsychotics, Nigrostriatal pathway dopamine antagonism, Parkinsonism and antipsychotics, Pseudoparkinsonism, Risperidone and motor control disorders, risperidone contraindications, risperidone contraindications/precautions, Risperidone dosage adjustments, Risperidone EPS case report, risperidone mechanism of action, Risperidone side effects, Risperidone-induced extrapyramidal side effects (EPS), Schizophrenia treatment and EPS, Second-generation antipsychotics

Risperidone induced Extrapyramidal Side Effects- Nigrostriatal Pathway: This pathway connects the substantia nigra to the striatum. It plays a key role in regulating voluntary movement. Blockade of dopamine in this pathway by antipsychotics like risperidone can lead to EPS, including tremors, rigidity, and bradykinesia (slow movement). Mesolimbic Pathway: This pathway runs from the ventral tegmental area (VTA) to the limbic system, which is involved in regulating emotions and reward. Dopamine blockade here helps reduce positive symptoms of schizophrenia, but it doesn't directly cause EPS. Mesocortical Pathway: This connects the VTA to the prefrontal cortex and is involved in cognition and emotional regulation. Dopamine disruption in this pathway can worsen negative symptoms or cognitive deficits but is not primarily involved in EPS. Tuberoinfundibular Pathway: This pathway runs from the hypothalamus to the pituitary gland, controlling prolactin secretion. Dopamine blockade here increases prolactin levels, but this pathway isn't directly related to EPS.

The mechanism behind EPS primarily involves the blockade of dopamine D2 receptors in the nigrostriatal pathway. This case report emphasizes the need for awareness of this risk when prescribing antipsychotic medications.” …

Read More…….Risperidone Induced Extrapyramidal Side Effects